OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.54 | -$0.31 | Beat |
| May 5, 2026 | -$0.81 | -$1.11 | Miss |
| Mar 12, 2026 | -$1.15 | -$0.99 | Beat |
| Nov 6, 2025 | -$1.20 | -$1.09 | Beat |
| Aug 12, 2025 | -$1.23 | -$1.14 | Beat |
| May 6, 2025 | -$1.32 | -$1.19 | Beat |